Doping in Esports and Mind Sports: The Real Evidence

Based on randomized controlled trials, prevalence surveys and the published anti-doping rulings of the governing bodies concerned. Every scientific claim carries a PMID or DOI.

---

Competitive chess has been drug-testing its players since the early 2000s. Competitive esports has been doing so since 2015. Competitive pinball, as far as any published rulebook shows, has never done it at all. Each of those facts has a specific cause, and none of them has much to do with evidence that the drugs in question work.

This article covers what people actually take, what the pharmacology says it does, what the one serious randomized trial in a mind sport actually found — which is not what the headlines said — and why the rules ended up where they are.

Key takeaways

• Chess began testing before anyone had demonstrated that a chess-enhancing drug existed. The motive was Olympic recognition, not evidence.
• The only randomized controlled trial of cognitive enhancers in a real mind sport found no effect on chess performance when all 3,059 games were analysed. The positive result appears only after controlling for game duration and excluding games lost on time.
• All three substances tested — modafinil, methylphenidate and caffeine — made players slower, not faster. They increased deliberation and increased losses on the clock.
• Esports acquired an anti-doping regime in roughly six weeks in 2015, triggered by a YouTube interview rather than a failed test.
• The world’s top-ranked bridge player was banned for a substance his own national federation publicly stated does nothing in bridge. That is what inheriting WADA’s list costs a mind sport.

Before it had a name

Long before any federation wrote a rule, mind sports ran on stimulants nobody classified as doping: coffee, tea, tobacco and later energy drinks. That is still overwhelmingly true.

A 2023 study of esports players by researchers at the Medical University of Warsaw found borderline-legal substance use to be close to universal: energy drinks 97.8%, coffee 81.6%, beer 29.7%, herbs 15.7% and over-the-counter medicines 15.1%. More than half of participants had heard about situations during tournaments involving performance-enhancing substance use (Słyk et al., 2023, Cureus 15(11):e48490, PMID 38074032).

This matters more than it looks. Every ethical argument about doping in mind sports has to explain why a substance that is pharmacologically an adenosine antagonist is fine when it arrives in a cup and a violation when it arrives in a capsule. Nobody has produced a satisfying answer, and the inconsistency shapes everything that follows.

Chess tests first, and chess revolts

FIDE introduced anti-doping testing at international events in the early 2000s in order to comply with International Olympic Committee and World Anti-Doping Agency requirements, as part of a campaign for chess to be recognised as an Olympic sport.

The testing was introduced under significant controversy, against a widespread belief that doping in chess was simply impossible. Research carried out by the Dutch chess federation reportedly failed to identify a single performance-enhancing substance for the game. All 802 tests administered at the 2002 Chess Olympiad came back negative.

The objection from players was not that they wanted to dope. It was that nobody had shown a chess-enhancing drug existed, and the testing therefore looked like a bureaucratic tax paid for an Olympic ambition the players did not share.

Enforcement problems followed almost immediately.

• 2004, Calviá Olympiad — two players refused to provide urine samples and had their scores cancelled.
• 2008, Dresden Olympiad — the case that reached international news. Vasyl Ivanchuk, then ranked third in the world, left the venue after a decisive final-round loss without completing his scheduled test. Refusal is normally treated as equivalent to a positive result, and a two-year ban was reported as possible. In January 2009, FIDE’s hearing panel imposed no penalty. Its reasoning: there had been a procedural failure — no designated Doping Control Officer was present at the USA–Ukraine match — and although the arbiter had attempted to instruct Ivanchuk in English, the panel accepted that he had not understood, English not being his first language, and that his state of mind after the loss led him to miss the test unintentionally.
• 2010 onward — a FIDE official commented that the work of the Medical Commission had made testing routine.
• 2013 — urine samples were taken from both players at the World Championship match in Chennai.
• 2014 — FIDE adopted a formal anti-doping code.

The Ivanchuk decision exposed the tension precisely. Two lower-profile players had been sanctioned for materially the same offence four years earlier; the world number three was not. Contemporary commentators made the obvious point: a federation cannot credibly test and simultaneously decline to enforce.

So — are chess players tested? Yes. At major FIDE events, including Chess Olympiads and World Championship matches. Testing is in-competition and sporadic rather than universal, and ordinary open or club tournaments are generally not tested.

2015: the Semphis moment

Esports had no anti-doping framework at all until a single interview created one.

In March 2015, Cloud9 competed at ESL One Katowice, a Counter-Strike: Global Offensive tournament with a $250,000 prize pool. In July, former player Kory “Semphis” Friesen said in a YouTube interview that the team had all been on Adderall during the event, and that it was audible in the voice comms. Nobody had accused him; he volunteered it.

The response was unusually fast for any sport. Within roughly two weeks, ESL announced a partnership with Germany’s Nationale Anti-Doping Agentur to develop an anti-PED policy described as fair, feasible and conclusive while respecting player privacy, with stated plans to engage WADA for enforcement in the US, Asia and Australia. Randomized testing began at ESL One Cologne the following month.

No player was retroactively punished — ESL could not prove the claim after the fact.

Two features of that origin story still shape esports anti-doping. First, the trigger was a disclosure, not a detection: the regime was built to answer a reputational problem. Second, it was built by a tournament organiser rather than a state-backed federation, which is why esports enforcement remains fragmented across organisers instead of unified under one code.

There is also a detail worth keeping. Friesen later told the New York Times he had tried the drug as a last resort during a losing spell, on the reasoning that it might help — and that it did not have the effect he hoped for. Cloud9 dropped him a month after the tournament for poor performance.

What people actually take, and what it does

The mechanism column explains why the rationale column exists. What it does not do is establish that the rationale is correct. For that there is exactly one serious trial.

Does any of it actually work?

Franke et al., 2017, European Neuropsychopharmacology 27(3):248–260 (PMID 28119083) is the only randomized controlled trial of cognitive enhancers conducted in a genuine competitive mind-sport task. It deserves reading in full rather than in headline.

Design. Phase IV, randomized, double-blind, placebo-controlled, 4×4 crossover. 39 male tournament chess players. Each played twenty 15-minute games per session against Fritz 12, calibrated to their own strength, and completed neuropsychological testing. Total games analysed: 3,059.

The finding, in the authors’ own terms. All three substances significantly increased average reflection time per game compared with placebo, which produced a significantly increased number of games lost on time under all three treatments. Treatment effects on chess performance were not seen when all 3,059 games were analysed. Only when controlling for game duration, and separately when excluding games lost on time, did modafinil and methylphenidate produce significantly higher scores — in the remaining 2,876 games.

The authors’ own conclusion is the useful sentence: the modifying effects of stimulants on complex cognitive tasks may result in particular from more reflective decision-making processes; when not under time pressure such effects may enhance performance, but under time constraints more reflective decision-making may not improve, or may even harm, complex task performance.

That is a more interesting result than “drugs improve chess,” and a considerably more useful one. These substances shift the speed–accuracy trade-off toward accuracy. Given unlimited time that is an improvement. Under a clock — the actual condition of competitive chess, and of every esports title — it cost players games outright.

Two things popular coverage of this study consistently omits. The figures reproduced almost everywhere online, that modafinil improved performance by about 15%, methylphenidate by about 13% and caffeine by about 9%, do not appear in the paper’s abstract; they entered circulation through press coverage. And the trial was played against a chess engine in a laboratory, not against humans in a tournament — a meaningful gap when part of what is being measured is psychological.

Evidence tier: Moderate. One well-designed trial, one game, 39 male participants. It is the best evidence that exists. It is not a literature.

Our guide to the cognitive benefits of caffeine shows the same pattern in the broader literature: real but small, and easier to detect in speed than in judgment.

What that does and does not imply for esports

Nobody has run the equivalent trial in competitive gaming. The chess result cannot simply be transferred, because the cognitive demands run close to opposite: chess rewards extended deliberation under a generous clock, while competitive shooters reward compressed reaction time and sustained vigilance across a long tournament day.

The plausible mechanism in esports is different — resistance to fatigue rather than better deliberation. That is a reasonable hypothesis. It has not been tested in a controlled trial.

One claim we are deliberately not making. No controlled trial retrieved supports the assertion that Adderall improves aim, reaction time or in-game performance in a first-person shooter. It is the single most-repeated claim in popular coverage of this topic and it currently has no trial behind it.

How common is it, really?

Prevalence data here is unusually poor, and the answer depends entirely on how you ask.

Legal stimulants: near-universal. The Warsaw figures above — 97.8% energy drinks, 81.6% coffee — are the baseline against which everything else should be read.

Prescription substances: much rarer in self-report. A 2025 survey of 1,924 German club chess players used the randomized response technique, a method specifically designed to elicit honest answers to incriminating questions by ensuring no individual answer can be linked to a respondent. Prevalence was somewhat lower among weaker and older players but comparable between over-the-board and online chess (Schu & Haller, 2025, Performance Enhancement & Health).

The methodological point is worth more than any single number. Self-report under-captures, peer estimates over-report, and the two approaches produce figures that differ by an order of magnitude. That gap is why quoted claims of an “epidemic” and claims of a “non-issue” can each cite a survey, and why any confident prevalence figure you read on this topic should be treated as an estimate with very wide error bars.

Who tests whom

The bridge case, which explains the whole system

In 2018, samples were collected from players at the World Bridge Series in Orlando under WADA Code provisions. One belonged to Geir Helgemo — then the world’s top-ranked bridge player — and returned an adverse analytical finding for clomifene and synthetic testosterone.

The WBF ruling was severe: ineligibility from bridge competition for one year, and revocation of the title, medal, awards and masterpoints Helgemo had won in the Rosenblum Cup 2018 and all other competitions within that World Bridge Series, with medals to be returned.

The president of the Norwegian Bridge Federation, Kari-Anne Opsal, stated publicly that it is a player’s responsibility not to take substances on the doping list even though in this instance they are not performance-enhancing in bridge.

That sentence is the entire argument in miniature. Because the WBF is IOC-recognised, it applies WADA’s Prohibited List — a list written for cycling and athletics, not card games. Bridge, recognised by the IOC as a mind sport in 1995, inherited the whole instrument. That is the trade a mind sport makes for Olympic legitimacy.

Esports took the opposite route: private codes built around the cognitive demands of the domain, which is a more rational instrument and a legally weaker one, binding only those events whose organisers adopt it.

And pinball, which took no route at all

The International Flipper Pinball Association maintains a detailed competition ruleset and a conduct code covering harassment, discrimination and player behaviour, with sanctions including suspension from the world rankings. Neither document contains an anti-doping provision, a prohibited list, or any testing requirement.

The irony deserves stating plainly. Of these disciplines, pinball has arguably the most plausible pharmacological attack surface — a game of reaction time, fine motor control and sustained visual tracking, exactly the domains where caffeine’s measured effects are clearest. It has no policy. Chess, where the mechanism turns out to be a double-edged shift in deliberation speed, tests urine at the Olympiad.

Testing regimes in mind sports track institutional ambition far more closely than they track pharmacological risk.

The ethical argument, both sides

This is genuinely contested, and the honest presentation is both cases rather than a verdict.

The case for prohibition. Competitive integrity requires that outcomes track skill and preparation, not pharmacy access. Prohibition also addresses coercion: where prize money is concentrated and careers are short, a permitted enhancer becomes a mandatory one, and players who would rather not take amphetamines face a choice between their health and their ranking. The safety concerns are real — amphetamines carry dependence liability and cardiovascular risk — and the duty-of-care argument applies with particular force in esports, where many competitors are very young.

The case against. Nobody has demonstrated a large effect in the actual competitive task; the one trial in a mind sport found the drugs made players lose games on time. Prohibiting something that may not work imposes real costs — testing expense, privacy intrusion, career-ending sanctions — for a speculative benefit. The caffeine inconsistency is unresolved. Therapeutic use exemptions create a two-tier system in which the same molecule is legitimate with a diagnosis and disqualifying without one, in a population where the relevant diagnosis is common and unevenly accessible. And there is a straightforward autonomy claim about adults making informed decisions regarding their own cognition.

Where the disagreement actually sits. Almost nobody argues competitors should be free to take anything, and almost nobody argues caffeine should be banned. The real dispute is where between those points the line falls, and on what basis — health risk, effect size, prescription status, or enforceability. Different federations have drawn it in different places, and none has offered a principled account of why.

Safety and legality

Everything here that is not caffeine or nicotine is a prescription medicine, and in most jurisdictions a controlled substance.

• Methylphenidate and amphetamine salts are Schedule II in the United States; possession without a prescription is a criminal offence. Both are prescription-only across the EU and UK.
• Modafinil is Schedule IV in the US and prescription-only in the EU and UK, with no marketing authorization for cognitive enhancement anywhere.
• All are prohibited in competition by WADA, meaning any competitor in a signatory federation — chess and bridge included — faces sanction regardless of local legality.

Amphetamine and methylphenidate carry cardiovascular effects, dependence liability and sleep disruption. Modafinil has known drug interactions and rare but serious adverse effects listed in its prescribing information. None of these compounds has been studied for long-term enhancement use in healthy people, because that trial would not receive ethical approval.

The sleep problem is the one nobody accounts for. A tournament schedule already compresses sleep. Stimulants taken to compensate degrade it further, and the cognitive cost of accumulated sleep debt reliably exceeds anything these compounds add. That is not a moral argument. It is arithmetic.

This article describes pharmacology and regulatory history. It is not guidance, and NootropicsJet does not recommend the off-label use of any prescription medicine.

What we still don’t know

• Whether any of these substances improve performance in a real-time task under a clock. The only trial suggests the time cost may exceed the accuracy gain.
• Whether the chess results transfer to reaction-dominated titles, where the speed–accuracy trade-off runs the other way.
• What actual prevalence is, within an order of magnitude.
• Whether effects in habituated users differ from those in naive users — which has direct consequences for what testing is even measuring.
• What long-term stimulant use does to competitors who start in their teens.

The bottom line

The history of doping in mind sports is mostly a history of regulation arriving ahead of evidence. Chess tested from the early 2000s because it wanted into the Olympics. Esports tested from 2015 because a player said something on camera. Bridge banned its best player for a substance its own national federation said did nothing in bridge. Pinball has never tested anyone.

Meanwhile the one controlled trial in the domain found that the drugs in question made players think longer and lose on time.

None of that means the rules are wrong. Coercion and youth safeguarding are serious arguments that stand independently of effect size. But anyone claiming that modafinil or Adderall confers a large, established advantage in competitive play is claiming more than the evidence supports — and so is anyone claiming they do nothing at all.

Frequently asked questions

Are chess players drug tested before tournaments? Yes, at the top level. FIDE has conducted anti-doping testing at international events since the early 2000s, including Chess Olympiads and World Championship matches, and applies WADA’s Prohibited List. Testing is in-competition and sporadic rather than universal; ordinary open and club tournaments are generally not tested.

Do performance-enhancing drugs work in chess? Partially, and with a catch. In the only randomized trial, treatment effects were not seen across all 3,059 games. Modafinil and methylphenidate improved scores only after controlling for game duration and excluding games lost on time — because all three substances made players deliberate longer and run out of clock.

Does Adderall actually help in esports? No controlled trial has tested this in an esports task. The closest evidence is from chess, where amphetamines were not tested but methylphenidate and modafinil were, and both increased deliberation enough to cost players games on the clock. Claims of a large advantage in competitive gaming are not backed by trial data.

Why was a bridge player banned for testosterone? Because the World Bridge Federation is IOC-recognised and therefore applies WADA’s Prohibited List, which was not written with card games in mind. Geir Helgemo received a one-year ban after a 2018 World Bridge Series sample returned synthetic testosterone and clomifene, and lost his titles and masterpoints from that event — while his own national federation stated the substances were not performance-enhancing in bridge.

Is caffeine considered doping? No. WADA removed caffeine from its Prohibited List and placed it on the monitoring programme. It is legal at every level of every mind sport discussed here, and use is close to universal — energy drink use was reported at 97.8% among surveyed esports players.

When did esports start drug testing? August 2015, at ESL One Cologne. The programme was created in roughly two weeks after Kory “Semphis” Friesen said in a July 2015 interview that his former team had used Adderall at ESL One Katowice that March. ESL partnered with Germany’s NADA and stated it would engage WADA for other regions.

---

This article is for informational and historical purposes only and is not medical advice. It describes substances used in competitive contexts; it does not recommend them. Methylphenidate, amphetamine salts and modafinil are prescription medicines in most jurisdictions and their use without a prescription is unlawful in many. Consult a qualified healthcare professional about any medication or supplement decision.

---

---

REFERENCES

1. Franke AG, Gränsmark P, Agricola A, et al. Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: A double-blind, randomised controlled trial. Eur Neuropsychopharmacol. 2017;27(3):248–260. doi:10.1016/j.euroneuro.2017.01.006. PMID 28119083
2. Słyk S, Zarzycki M, Grudzień K, Majewski G, Jasny M, Domitrz I. The Prevalence and Outlook of Doping in Electronic Sports (Esports). Cureus. 2023;15(11):e48490. doi:10.7759/cureus.48490. PMID 38074032
3. Schu K, Haller N. Cheating and Doping in Chess – A Survey among 1,924 German Club Players using the Randomized Response Technique. Performance Enhancement & Health. 2025. doi:10.1016/j.peh.2025.100344
4. Kløve K, Petersen A. A systematic review and meta-analysis of the acute effect of caffeine on attention. Psychopharmacology (Berl). 2025;242(9):1909–1930. PMID 40335666
5. World Bridge Federation Anti-Doping Hearing Panel ruling in the matter of Geir Helgemo, 2019
6. FIDE Anti-Doping Regulations (code adopted 2014); FIDE Doping Hearing Panel decision, January 2009
7. ESL anti-doping programme announcement, July 2015, with Nationale Anti-Doping Agentur
8. PAPA/IFPA Complete Competition Ruleset; IFPA Conduct Code
9. World Anti-Doping Agency Prohibited List, class S6 stimulants; WADA Monitoring Programme